Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01970306 · ClinicalTrials.gov registry record · Phase 2
Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material
A Phase 2 study of Esophageal Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 4
- Study locations
NCT01970306: Completed Phase 2 study of Esophageal Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01970306 is a Phase 2 study of Esophageal Adenocarcinoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 78 participants, below the 307-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (75% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01970306, a Phase 2 study of Esophageal Adenocarcinoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to see if implanting MatriStem will lower the risk of one of the more common complications after stomach or esophagus surgery.
Primary Outcome
Anastomotic leak will be assessed by clinical observation and one postoperative contrast study (thin-barium Gastrografin or Omnipaque swallow)
Conditions Studied
Interventions
- DEVICE MatriStem PSM
Study Locations (4)
New York
- Memorial Sloan Kettering West Harrison - Harrison
- Memorial Sloan Kettering Cancer Center - New York
New Jersey
- Memorial Sloan Kettering Cancer Center - Basking Ridge
Texas
- Md Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2013-10-18 |
| Est. Completion | 2023-02-24 |
| Phase | Phase 2 |
What the finished NCT01970306 record still lists
NCT01970306 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 307-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which MatriStem PSM is the first listed.
NCT01970306 reports a single indexed study location in New York, New Jersey, Texas.
Frequently Asked Questions
What is clinical trial NCT01970306 about?
NCT01970306 is a clinical study titled "Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material". The purpose of this study is to see if implanting MatriStem will lower the risk of one of the more common complications after stomach or esophagus surgery.
What is the current status of trial NCT01970306?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2013-10-18. Estimated completion is 2023-02-24.
What conditions does trial NCT01970306 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma.
What interventions are being tested in trial NCT01970306?
The interventions under investigation include: MatriStem PSM (DEVICE).
Who is sponsoring clinical trial NCT01970306?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01970306 being conducted?
This trial has 4 study locations across New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01970306's enrollment target sits among peer trials
78 20th of 43 higher than 23 of 43 other Esophageal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
RECRUITING · Phase 2
-
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Obeticholic Acid for Prevention in Barrett's Esophagus
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI